• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Notable Labs Ltd.

    8/9/24 4:01:56 PM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTBL alert in real time by email
    SC 13D/A 1 d712714dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Notable Labs, Ltd.

    (Name of Issuer)

    Ordinary Shares, nominal value of NIS 0.35 per share

    (Title of Class of Securities)

    M7517R107

    (CUSIP Number)

    James Kim

    c/o Builders VC

    601 California Street, Suite, 700

    San Francisco, CA 94108

    (415) 692-1720

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 8, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

     

     

     


    CUSIP No. M7517R107

     

     1   

     NAME OF REPORTING PERSON.

     

     Builders VC Fund I (Canada), L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     SC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Alberta, Canada

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER

     

     305,306 Ordinary Shares

     Warrant to purchase up to 4,713 Ordinary Shares

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER

     

     305,306 Ordinary Shares

     Warrant to purchase up to 4,713 Ordinary Shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     305,306 Ordinary Shares

     Warrant to purchase up to 4,713 Ordinary Shares

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     3.2%(1)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on an aggregate of approximately 9,674,496 Ordinary Shares issued and outstanding as of June 10, 2024, according to the Amendment No. 1 on Form S-1 (File No. 333-280357) filed by the Issuer with the SEC on July 1, 2024.


    CUSIP No. M7517R107

     

     1   

     NAME OF REPORTING PERSON.

     

     Builders VC Fund I, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     SC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER

     

     1,846,324 Ordinary Shares

     Warrant to purchase up to 28,498 Ordinary Shares

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER

     

     1,846,324 Ordinary Shares

     Warrant to purchase up to 28,498 Ordinary Shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,846,324 Ordinary Shares

     Warrant to purchase up to 28,498 Ordinary Shares

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     19.3%(1)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on an aggregate of approximately 9,674,496 Ordinary Shares issued and outstanding as of June 10, 2024, according to the Amendment No. 1 on Form S-1 (File No. 333-280357) filed by the Issuer with the SEC on July 1, 2024.


    CUSIP No. M7517R107

     

     1   

     NAME OF REPORTING PERSON.

     

     Builders VC Entrepreneurs Fund I, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     SC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER

     

     132,980 Ordinary Shares

     Warrant to purchase up to 2,053 Ordinary Shares

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER

     

     132,980 Ordinary Shares

     Warrant to purchase up to 2,053 Ordinary Shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     132,980 Ordinary Shares

     Warrant to purchase up to 2,053 Ordinary Shares

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     1.4%(1)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on an aggregate of approximately 9,674,496 Ordinary Shares issued and outstanding as of June 10, 2024, according to the Amendment No. 1 on Form S-1 (File No. 333-280357) filed by the Issuer with the SEC on July 1, 2024.


    CUSIP No. M7517R107

     

     1   

     NAME OF REPORTING PERSON.

     

     James Jimin Kim

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     SC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER

     

     2,284,610 Ordinary Shares

     Warrant to purchase up to 35,264 Ordinary Shares

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER

     

     2,284,610 Ordinary Shares

     Warrant to purchase up to 35,264 Ordinary Shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,284,610 Ordinary Shares

     Warrant to purchase up to 35,264 Ordinary Shares

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     23.9%(1)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on an aggregate of approximately 9,674,496 Ordinary Shares issued and outstanding as of June 10, 2024, according to the Amendment No. 1 on Form S-1 (File No. 333-280357) filed by the Issuer with the SEC on July 1, 2024.


    Explanatory Note

    This Amendment No. 1 (this “Amendment”) amends and supplements the Schedule 13D originally filed by the undersigned with the Securities and Exchange Commission on October 19, 2023 (the “Original Schedule 13D” and, as amended by this Amendment, this “Schedule 13D”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D are materially unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.

    Item 4 - Purpose of Transaction

    Item 4 of the Schedule 13D is hereby amended and restated as follows:

    The Reporting Persons acquired beneficial ownership of the Ordinary Shares described herein for investment purposes with the aim of increasing the value of their investments in the Issuer. Subject to applicable legal requirements, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions on such terms and at such times as each may decide. In addition, depending upon the factors referred to herein, the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time. The Reporting Persons may also engage, from time to time, in ordinary course transactions with financial institutions with respect to the securities described herein.

    The Reporting Persons have engaged and intend to continue to engage in discussions with certain members of the Issuer’s board of directors and management team regarding the Issuer’s business, operations, financial condition, strategic plans, potential financing transactions, governance, performance, and potential avenues to enhance stockholder value, as well as other matters related to the Issuer, and have engaged and may continue to engage in an exchange of ideas and views with other stockholders, industry analysts and other interested parties with respect to the foregoing.

    The Reporting Persons have determined to consider, evaluate and discuss with the Issuer and other stockholders, industry analysts and other interested parties one or more potential transactions or undertakings which may result in one or more of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act, including, but not limited to, the acquisition by any person of additional securities of the Issuer pursuant to a financing transaction or otherwise. The Reporting Persons do not intend to amend this Schedule 13D in relation to such discussions and evaluation unless and until an agreement has been reached, except if facts and circumstances otherwise require the Reporting Persons to do so.

    The Reporting Persons retain the right to change their investment intent at any time and there is no assurance the Reporting Persons will continue discussion or evaluation of any transactions or that any transaction will be pursued and, if pursued, will be consummated. Moreover, any actions described in this Item 4 that the Reporting Persons might undertake may be made at any time and from time to time and such determinations will be dependent upon the Reporting Persons’ review of numerous factors, including, but not limited to, an ongoing evaluation of the Issuer’s business, financial condition, operations and prospects; price levels of the Issuer’s securities; general market, industry and economic conditions; and other future developments affecting the Issuer.

    Other than as described in this Item 4 above, the Reporting Persons do not have any current plans or proposals that relate to or that would result in any of the transactions or other matters specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: August 9, 2024

     

      

    /s/ James Jimin Kim

    Name: James Jimin Kim

              
    BUILDERS VC FUND I (CANADA), L.P.   

    By: Builders VC GP I, LLC, its general partner

     

    /s/ James Kim

    Name: James Kim

    Title: Managing Member

      
    BUILDERS VC FUND I, L.P.   

    By: Builders VC GP I, LLC, its general partner

     

    /s/ James Kim

    Name: James Kim

    Title: Managing Member

      
    BUILDERS VC ENTREPRENEURS FUND I, L.P.   

    By: Builders VC GP I, LLC, its general partner

     

    /s/ James Kim

    Name: James Kim

    Title: Managing Member

      
    Get the next $NTBL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTBL

    DatePrice TargetRatingAnalyst
    9/20/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $NTBL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notable Labs to Present Data on September 4th at SOHO 2024

      Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that the Company will present an overview of the Phase 2 program and additional data from preclinical studies evaluating volasertib for acute myeloid leukemia (AML) at the twelfth annual meeting of the Society for Hematologic Oncology (SOHO 2024), b

      8/29/24 7:30:00 AM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Announces CEO Transition

      Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that Thomas A. Bock, MD has resigned from his positions as Chief Executive Officer (CEO) and member of the Board of Directors of the Company, effective today. Joseph Wagner, PhD, the Company's Chief Scientific Officer (CSO), has been appointed as interim CEO. T

      8/26/24 4:05:00 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

      FOSTER CITY, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of "Clearance to Proceed" from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming mo

      7/24/24 7:30:00 AM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTBL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Notable Labs downgraded by JMP Securities

      JMP Securities downgraded Notable Labs from Mkt Outperform to Mkt Perform

      9/20/24 7:46:25 AM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTBL
    SEC Filings

    See more

    $NTBL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $NTBL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NTBL
    Leadership Updates

    Live Leadership Updates

    See more
    • Notable Labs Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Notable Labs, Ltd. (0001603207) (Filer)

      10/16/24 4:30:30 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Ltd. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

      8-K - Notable Labs, Ltd. (0001603207) (Filer)

      10/15/24 6:13:51 AM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Ltd. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

      8-K - Notable Labs, Ltd. (0001603207) (Filer)

      9/19/24 4:05:18 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Notable Labs Ltd.

      SC 13D/A - Notable Labs, Ltd. (0001603207) (Subject)

      8/9/24 4:01:56 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Zagger Kaile A. claimed no ownership of stock in the company (SEC Form 3)

      3 - Notable Labs, Ltd. (0001603207) (Issuer)

      9/26/24 11:07:19 AM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Patsi Tuomo was granted 65,247 units of Ordinary Shares (SEC Form 4)

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      5/10/24 5:18:35 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Wagner Joseph P

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      5/10/24 5:17:04 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Announces CEO Transition

      Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that Thomas A. Bock, MD has resigned from his positions as Chief Executive Officer (CEO) and member of the Board of Directors of the Company, effective today. Joseph Wagner, PhD, the Company's Chief Scientific Officer (CSO), has been appointed as interim CEO. T

      8/26/24 4:05:00 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care